RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1
RAF1 作为 KRAS 驱动的肺腺癌的独立治疗靶点：联合靶向 ARAF、EGFR 或 DDR1 并无额外疗效
期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0341778
de-la-Puente-Ovejero, Laura; Fernández-Rodríguez, Ana; Francoz, Sarah; Aizpurua, Gonzalo; Lomba-Riego, Lucía; Drosten, Matthias; Guerra, Carmen; Musteanu, Mónica; Barbacid, Mariano; García-Alonso, Sara
DDR1
肿瘤
肿瘤免疫
EGF
EGFR
ARAF
RAS
RAF1
